We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fecal Occult Blood Screening Increases High-Risk Polyp Detection

By LabMedica International staff writers
Posted on 12 Jan 2015
Print article
Image: Biopsy slide of a classic tubular adenoma polyp that is precancerous (Photo courtesy of Dr. Scot M. Lewey).
Image: Biopsy slide of a classic tubular adenoma polyp that is precancerous (Photo courtesy of Dr. Scot M. Lewey).
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk precancerous adenomas, sometimes called polyps, by 89%.

As part of the screening program, a prescreening procedure is undertaken by a general practitioner or gastroenterologist to identify patients who are at higher than average risk of colorectal cancer based on their family history and those patients were invited to undergo colonoscopy rather than fecal occult blood test (FOBT).

Scientists at the University of Burgundy (INSERM Unité 866; Dijon, France) evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began in 2003. The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008. The investigators showed that 38.7% of these people had high-risk adenomas, meaning they were larger than one centimeter in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia.

Of 1,179 patients studied, 889 underwent colonoscopy, and overall, 253 colorectal neoplasias were diagnosed including 35 cancers, and adenomas in 219 patients. A total of 209 advanced adenomas were diagnosed. The authors calculated that the positive predictive value of colonoscopy was 3.9% for cancer, 12.9% for advanced adenoma, and 25% for adenoma overall. This compared poorly to the positive predictive value in the average risk population selected by a positive FOBT. In this population, the positive predictive value of the colonoscopy done after positive test in their administrative area ranges from 7.5% to 10% for cancer, from 15% to 27% for advanced adenoma and between 32% and 37% for adenoma. The immunochemical fecal occult blood tests outperformed guaiac tests for the detection of colorectal cancer and advanced adenoma. They have doubled the detection rate of invasive colorectal cancer, mostly at early stages, and led to a fourfold increase in the detection rate of noninvasive colorectal cancer and advanced adenomas.

Hans-Joachim Schmoll, MD, PhD, a professor of Hematology and Oncology, at the Martin Luther University Halle-Wittenberg (Halle, Germany) said, “In this study it was shown that a prediction for screening colonoscopy using high risk features—based on family history—revealed a less positive predictive value than prescreening by FOBT with follow-up of those who have a positive result.” The study was presented at the European Society for Medical Oncology Congress held September 26–30, 2014, in Madrid (Spain).

Related Links:

University of Burgundy 
Martin Luther University Halle-Wittenberg


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.